Tubular dysfunction after peritonectomy and chemohyperthermic treatment with cisplatin

In Vivo. 2006 Nov-Dec;20(6A):703-6.

Abstract

Peritoneal carcinomatosis has always been regarded as a contraindication in traditional cancer surgery treatment; however, good results have been reported by using new combined medical-surgical loco-regional techniques. Peritonectomy and chemohyperthermic perfusion with cisplatinum (CIIP) seem to play a central role in obtaining a better survival rate than with the traditional procedures, even though there is a cisplatinum nephrotoxic effect. The aim of this study was to investigate entity and type of renal injury after CIIP. Forty-two patients (12 males and 30 females) with recurrent or primary peritoneal carcinomatosis who underwent peritonectomy and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy with cisplatin were enrolled. A significant worsening in renal function was observed on the third post-operative day and this condition then persisted for three months. A reduction in estimated-Glomerular Filtration Rate (e-GFR) and an alteration in the albumin:creatinine ratio proved tubular injury. On the third post-operative day after cisplatinum administration, a high toxicity peak was found following platinum free fraction excretion. Proximal tubular injury was confirmed even at the three month analysis. A significant correlation between the total protein reduction rate and the decrease in renal function was established. In relation to that, the platinum free fraction could increase because of a binding protein shortage and the nephrotoxic effect could be enhanced due to platinum accumulation within the post-operative period. This finding suggests that the higher the protein reduction is, the lower the e-GFR determination is at three months.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Albuminuria / diagnosis
  • Albuminuria / urine
  • Antineoplastic Agents / adverse effects*
  • Carcinoma / therapy*
  • Chemotherapy, Cancer, Regional Perfusion
  • Cisplatin / adverse effects*
  • Combined Modality Therapy
  • Creatine / urine
  • Female
  • Glomerular Filtration Rate / drug effects
  • Humans
  • Hyperthermia, Induced
  • Kidney Diseases / chemically induced*
  • Kidney Diseases / metabolism
  • Kidney Diseases / physiopathology
  • Kidney Tubules / drug effects*
  • Kidney Tubules / metabolism
  • Kidney Tubules / physiopathology
  • Male
  • Middle Aged
  • Peritoneal Neoplasms / drug therapy*
  • Peritoneum / surgery*

Substances

  • Antineoplastic Agents
  • Creatine
  • Cisplatin